Navigation Links
Lilly Declares Second-Quarter Dividend
Date:4/21/2008

INDIANAPOLIS, April 21 /PRNewswire-FirstCall/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the second quarter of 2008 of $0.47 a share on outstanding common stock. This is the same dividend as was paid in the first quarter and maintains the annual indicated dividend rate for 2008 of $1.88 per share.

The dividend is payable June 10, 2008, to shareholders of record at the close of business on May 15, 2008.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com . F-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Lilly to Streamline Indianapolis Manufacturing and Engineering Operations
2. Lilly Adjusts Time of Conference Call for First Quarter 2008 Financial Results Announcement
3. Lilly Sets Date and Conference Call for First Quarter 2008 Financial Results Announcement
4. State of Alaska and Eli Lilly and Company Reach Agreement to Settle Zyprexa Lawsuit
5. Statement from Eli Lilly and Company: Response to Todays New York Times Article, Lilly E-Mail Discussed Off-Label Drug Use
6. Lilly Grants $4.4 Million to the WHO for MDR-TB Program Expansion
7. Newly Labeled Therapies for Neuropathic Pain, Including Drugs From Pfizer and Eli Lilly, Will Drive Growth in the Chronic Pain Drug Market
8. Mental Health Parity Laudable, But House Legislation Would Put Medicaid Patients at Risk, Lilly Says
9. FDA Issues Not-Approvable Letter for Lillys Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Lilly and Partners In Health, Brigham and Womens Hospital Team Up to Fight MDR-TB in Former Soviet Republics
11. Michael L. Eskew Elected to Lilly Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... 23, 2017 , ... "ProRandom is a set of camera tools that allow video editors to ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , With ... with video footage. ProRandom works by using a virtual camera to create the illusion ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... (OREF), in partnership with the American Society of Anesthesiologists® (ASA®), the Foundation ... the American Academy of Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... “The Inn at the Mill”: a ... unexpected fears in her quest to become happy and content. , “The Inn at ... Pennsylvania, has also lived in Germany and Vermont and is now living in Berks County ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching communities and ... resources have been developed for use by nutrition educators and influencers within ...
(Date:1/23/2017)... ... ... Infallible Characteristics of Christ”: a fascinating and entrancing novel exploring the gifts and ... author, Rev. Dr. Robert W. Thomas, the third of seven siblings. He was a ... pastor for over fifteen years. He is a graduate of N.C. College of Theology ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... The global  anxiety disorders and depression treatment market  is ... incidence of depression worldwide is anticipated to drive the market growth in the ... demand for antidepressants in the recent years. Continue ... ... ...
(Date:1/23/2017)... Spain , January 23, 2017 ... clinical-stage biopharmaceutical company focused on treatments for calcification ... been enrolled in the Phase IIb "CaLIPSO Study" ... treatment of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) ... patients, in the last stage of chronic kidney ...
(Date:1/23/2017)... Just two weeks remain until legal experts and senior industry leaders involved ... London to discuss the flow of pharmaceutical products post Brexit ... Trade 2017 . In the run up to the show, ... to read in the event download centre . ... Some of those confirmed include: ...
Breaking Medicine Technology: